SCHEMBL2326461

SCHEMBL2326461

CCOC(=O)[C@@H](CC)OS(=O)(=O)C(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
POLB P06746 1/20 0.34
ALDH1A1 P00352 3/20 0.32
LMNA P02545 1/20 0.31
PIN1 Q13526 1/20 0.31
AR P10275 1/20 0.31
ATM Q13315 1/20 0.31
CXCR2 P25025 1/20 0.31
HPGD P15428 2/20 0.30
PTGDR2 Q9Y5Y4 1/20 0.30
KMT2A Q03164 4/20 0.30
TP53 P04637 1/20 0.30
MAPK1 P28482 1/20 0.30
RAB9A P51151 1/20 0.30
BCL2A1 Q16548 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
TLR9 Q9NR96 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15922161 1.00 HSD17B10 (0.35) HSD17B10MAPTHTTSMN1; SMN2POLB
SCHEMBL9327185 0.86 HTT (0.36) HSD17B10MAPTHTTSMN1; SMN2POLB
SCHEMBL14003053 0.86 HTT (0.36) HSD17B10MAPTHTTSMN1; SMN2POLB
SCHEMBL2332745 0.86 CA1 (0.38) HSD17B10MAPTHTTSMN1; SMN2CXCR2
SCHEMBL21261493 0.86 CA1 (0.38) HSD17B10MAPTHTTSMN1; SMN2CXCR2
SCHEMBL15382587 0.86 CA1 (0.38) HSD17B10MAPTHTTSMN1; SMN2CXCR2
SCHEMBL3069494 0.83 SMN1; SMN2 (0.35) SMN1; SMN2PTGDR2
SCHEMBL2327079 0.83 SMN1; SMN2 (0.35) SMN1; SMN2PTGDR2
SCHEMBL2797629 0.83 SMN1; SMN2 (0.35) SMN1; SMN2PTGDR2
SCHEMBL7228766 0.83 AAK1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 US disclosed
EP-1806339-B1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB PHARMA SA (BE) 2011-08-17 EP disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 US disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES CYP2F1, CYP3A5, SULT1E1 HSD17B10 1966/4885MAPT 1791/4885HTT 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.